Effect of troglitazone on steady-state pharmacokinetics of digoxin

Journal of Clinical Pharmacology

Volumn 38, Issue 2, 1998, Pages 178-183

  Loi, Cho Ming ^a   Knowlton, Philip W ^a   Stern, Ralph ^a   Randinitis, Edward J ^a   Vassos, Artemios B ^a   Koup, Jeffrey R ^a   Sedman, Allen J ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; TROGLITAZONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG TOLERABILITY; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; RADIOIMMUNOASSAY; STEADY STATE;

EID: 0031931104     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04408.x     Document Type: Article

References (23)

1. Horikoshi H, Yoshioka T, Kawasaki T, Nakamura K, Matsunuma N, Yamaguchi K, Sasahara K: Troglitazone (CS-045), a new antidiabetic drug. Annu Rep Sankyo Res Lab 1994;46:1-57.
2. Lebovitz HE, Feinglos MN: Sulfonylurea drugs: mechanism of antidiabetic action and therapeutic usefulness. Diabetes Care 1987;1:189-198.
3. Bailey CJ, Turner RC: Metformin. N Engl J Med 1996;334:574-579.
4. Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA: In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 1990;39:1056-1062.
5. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988;37:1549-1558.
6. Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G, Shiraishi I: Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 1991;14:1083-1086.
7. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992;15:192-203.
8. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky JM: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994;331:1188-1193.
9. Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T, Sugiyama Y: Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 1996;277:1630-1641.
10. Loi CM, Randinitis EJ, Vassos AB, Kazierad DJ, Koup JR, Sedman A: Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study. J Clin Pharmacol 1997;37:1114-1120.
11. Loi CM, Alvey CW, Randinitis EJ, Abel R, Young MA, Koup JR: Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites. J Clin Pharmacol 1997;37;1038-1047.
12. Aronson JK: Clinical pharmacokinetics of digoxin 1980. Clin Pharmacokinet 1980;5:137-149.
13. Rodin SM, Johnson BF: Pharmacokinetic interactions with digoxin. Clin Pharmacokinet 1988;15:227-244.
14. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
15. Gibaldi M, Perrier D: Pharmacokinetics. Second edition. New York: Marcel Dekker, 1982.
16. Reuning RH, Geraets DR, Rocci ML, Vlasses PH: Digoxin. In, Evans WE, Schentag JJ, Jusko WJ (eds.): Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Third edition. Vancouver, WA: Applied Therapeutics, 1992;20-25.
17. Albert KS, Ayres JW, DiSanto AR, Weidler DJ, Sakmar E, Hallmark MR, et al: Influence of kaolin-pectin suspension on digoxin bioavailability. J Pharm Sci 1978;67:1582-1586.
18. Brown DD, Juhl RP: Decreased bioavailability of digoxin due to antacids and kaolin-pectin. New Engl J Med 1976;295:1034-1037.
19. Brown DD, Juhl RP, Warner SL: Decreased bioavailability of digoxin due to hypocholesterolemic intervention. Circulation 1978;58:164-172.
20. Brown DD, Schmid J, Long RA, Hull JH: A steady-state evaluation of the effects of propantheline bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules. J Clin Pharmacol 1985;25:360-364.
21. Johnson BF, Wilson J, Marwaha R, Hoch K, Johnson J: The comparative effects of verapamil and a new dihydropyridine calcium channel blocker on digoxin pharmacokinetics. Clin Pharmacol Ther 1987;42:66-71.
22. Pedersen KE, Dorph-Pedersen A, Hvidt S, Klitgaard NA, Nielsen-Kudsk F: Digoxin-verapamil interaction. Clin Pharmacol Ther 1981;30:311-316.
23. Schenck-Gustafsson K, Dahlqvist R: Pharmacokinetics of digoxin in patients subjected to quinidine-digoxin interaction. Br J Clin Pharmacol 1981;11:181-186.